Chromogen

Hardy Diagnostics awarded Manual Microbiology agreement with Premier, Inc.

Retrieved on: 
Tuesday, February 28, 2023
Premier, Inc., Learning, Trust, Culture, Hardy Diagnostics, Diagnosis, Hardy, Microbiology, Disease, Hospital, Partnership, Marketing, Business, Chromogen, Clinical collaboration, Medical device

SANTA MARIA, Calif. , Feb. 28, 2023 /PRNewswire/ -- Hardy Diagnostics has been awarded a national group purchasing agreement for Manual Microbiology with Premier, Inc.

Key Points: 
  • SANTA MARIA, Calif. , Feb. 28, 2023 /PRNewswire/ -- Hardy Diagnostics has been awarded a national group purchasing agreement for Manual Microbiology with Premier, Inc.
  • Effective 2/1/23, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Microbiology products.
  • Hardy Diagnostics awarded national group purchasing agreement for manual microbiology with Premier, Inc.
    "We are so excited and proud to be part of the Premier network and look forward to sharing our story and learning how we can best support Premier members.
  • All Hardy Diagnostics' products offered are aimed at providing clinical laboratories across the country with tools for the detection and diagnosis of disease.

Astria Therapeutics Presents Additional Data Supporting STAR-0215 Profile as a Long-Acting Preventative Therapy for Hereditary Angioedema at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting

Retrieved on: 
Friday, February 24, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Safety, Therapy, Allergy, Half-life, Prekallikrein, Plasma kallikrein, Hereditary angioedema, Protease, Plasma, American Academy of Allergy, Asthma, and Immunology, HAE, ADAS, Asthma, American Academy, Pharmaceutical industry, Western blot, Chromogen

Additionally, there were no clinically significant changes in laboratory assessments, and there were no treatment-emergent anti-drug antibodies (ADAs) detected.

Key Points: 
  • Additionally, there were no clinically significant changes in laboratory assessments, and there were no treatment-emergent anti-drug antibodies (ADAs) detected.
  • At Day 84, mean concentrations remained above the threshold for potential efficacy after a single 300 mg subcutaneous dose.
  • Initial results from a Phase 1a trial in healthy subjects support STAR-0215’s target profile: a long-acting preventative therapy, best-in-class PK profile, and dosing once every three months or less frequently.
  • The Phase 1b/2 ALPHA-STAR trial evaluating STAR-0215 in people living with HAE is ongoing, with initial results from single and multiple dose cohorts expected in mid-2024.